Potentially actionable molecular alterations include agnostic targets (NTRK1-2-3 [15], RET fusions [28], BRAF V600E mutations [29], microsatellite instability [30], high tumor mutational burden [31]), or tissue-specific targets, such as EGFR mutation in NSCLC [18] or PIK3CA mutations in breast cancer [32]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.